

# Dongmei Lin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2587627/publications.pdf>

Version: 2024-02-01

42  
papers

1,367  
citations

567281

15  
h-index

361022

35  
g-index

47  
all docs

47  
docs citations

47  
times ranked

2369  
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of multiplex immunofluorescence and digital image analysis for programmed death-ligand 1 expression and immune cell assessment in non-small cell lung cancer: comparison with conventional immunohistochemistry. <i>Journal of Clinical Pathology</i> , 2022, 75, 452-458.	2.0	2
2	Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer. <i>Modern Pathology</i> , 2022, 35, 403-411.	5.5	28
3	Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer. <i>Modern Pathology</i> , 2022, 35, 218-227.	5.5	8
4	Percentage of Newly Proposed High-Grade Patterns Is Associated with Prognosis of Pathological T1-2N0M0 Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	3
5	ASO Author Reflections: High Percentage of Newly Proposed High-Grade Patterns (Micropapillary,) Tj ETQq1 1 0.784314 rgBT /Overlook Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
6	A prognostic classification based on the International Association for the Study of Lung Cancer histologic grading and immunoscore in <i>KRAS</i> mutant invasive non-mucinous adenocarcinoma. <i>Thoracic Cancer</i> , 2022, 13, 1050-1058.	1.9	5
7	Feasibility of using <i>P16</i> methylation as a cytologic marker for esophageal squamous cell carcinoma screening: A pilot study. <i>Cancer Medicine</i> , 2022, 11, 4033-4042.	2.8	8
8	Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients. <i>Journal of Translational Medicine</i> , 2022, 20, 114.	4.4	7
9	ASO Visual Abstract: Percentage of Newly Proposed High-Grade Patterns Is Associated With Prognosis of Pathologic T1-2N0M0 Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
10	Neoadjuvant <i>PD-1</i> inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung. <i>Thoracic Cancer</i> , 2022, 13, 442-452.	1.9	4
11	Synchronous and metachronous metastasis to renal parenchyma of esophageal squamous cell carcinoma: two case reports and review of the literature. <i>Translational Cancer Research</i> , 2021, 10, 1135-1143.	1.0	0
12	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 686-696.	1.1	13
13	Localized ALK-positive histiocytosis in a Chinese woman: report of a case in the lung with a novel EML4-ALK rearrangement. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 1079-1083.	2.8	7
14	Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer. <i>Diagnostic Pathology</i> , 2021, 16, 38.	2.0	12
15	Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer. <i>Modern Pathology</i> , 2021, 34, 1990-1998.	5.5	13
16	Evaluation of the Impact of Intratumoral Heterogeneity of Esophageal Cancer on Pathological Diagnosis and <i>P16</i> Methylation and the Representativity of Endoscopic Biopsy. <i>Frontiers in Oncology</i> , 2021, 11, 683876.	2.8	2
17	A Review of Artificial Intelligence in Precise Assessment of Programmed Cell Death-ligand 1 and Tumor-infiltrating Lymphocytes in Non-Small Cell Lung Cancer. <i>Advances in Anatomic Pathology</i> , 2021, 28, 439-445.	4.3	7
18	PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study. <i>Journal of Cancer</i> , 2021, 12, 7390-7398.	2.5	6

#	ARTICLE	IF	CITATIONS
19	Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 407-416.	2.5	7
20	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 499-519.	1.1	203
21	Napsin A Expression in Subtypes of Thyroid Tumors: Comparison with Lung Adenocarcinomas. <i>Endocrine Pathology</i> , 2020, 31, 39-45.	9.0	13
22	Updates in the advances of sporadic medullary thyroid carcinoma: from the molecules to the clinic. <i>Gland Surgery</i> , 2020, 9, 1847-1856.	1.1	10
23	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	1.1	182
24	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1599-1610.	1.1	234
25	Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers. <i>Pathology and Oncology Research</i> , 2020, 26, 2577-2585.	1.9	30
26	A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy. <i>Lung Cancer</i> , 2019, 130, 135-142.	2.0	10
27	The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series. <i>Cancer Biology and Medicine</i> , 2019, 16, 811-821.	3.0	14
28	Co-occurring genetic alterations and primary EGFR T790M mutations detected by next-generation sequencing in pre-TKI treated patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13128-e13128.	1.6	0
29	Prognostic value of PD-L1 expression in combination with CD8+ TILs density in patients with surgically resected non-small cell lung cancer. <i>Cancer Medicine</i> , 2018, 7, 32-45.	2.8	48
30	Chinese multidisciplinary expert consensus: Guidelines on percutaneous transthoracic needle biopsy. <i>Thoracic Cancer</i> , 2018, 9, 1530-1543.	1.9	17
31	Clonality assessment of multifocal lung adenocarcinoma by pathology evaluation and molecular analysis. <i>Human Pathology</i> , 2018, 81, 261-271.	2.0	13
32	A comparison of QuantStudio <sup>®</sup> 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients. <i>Cancer Management and Research</i> , 2018, Volume 10, 115-121.	1.9	16
33	Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors. <i>Diagnostic Pathology</i> , 2018, 13, 30.	2.0	43
34	CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients. <i>International Journal of Hematology</i> , 2018, 108, 254-266.	1.6	14
35	PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma. <i>Diagnostic Pathology</i> , 2017, 12, 72.	2.0	25
36	Primary Tumor Location Is a Useful Predictor for Lymph Node Metastasis and Prognosis in Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2017, 18, e49-e55.	2.6	28

#	ARTICLE	IF	CITATIONS
37	Estimation of the Survival of Patients With Lung Squamous Cell Carcinoma Using Genomic Copy Number Aberrations. <i>Clinical Lung Cancer</i> , 2016, 17, 68-74.e5.	2.6	3
38	PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. <i>Human Pathology</i> , 2016, 55, 182-189.	2.0	58
39	Responses to crizotinib in patients with <i>ALK</i> -positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence <i>in situ</i> hybridization (FISH)-negative. <i>Oncotarget</i> , 2016, 7, 64410-64420.	1.8	21
40	Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 52862-52869.	1.8	9
41	Intratumoral Heterogeneity of <i>ALK</i> -Rearranged and <i>ALK</i> / <i>EGFR</i> Coaltered Lung Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3701-3709.	1.6	129
42	Genome-wide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamous-cell carcinoma. <i>Nature Genetics</i> , 2013, 45, 632-638.	21.4	97